Drug Channels

NOVEMBER 11, 2022

Today’s guest post comes from Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. Click here to learn about AmerisourceBergen’s Cell and Gene Therapy solutions for biopharma companies, providers, and patients. Read on for Lung-I’s insights.

Gene Therapy 89

Gene Therapy Gene Manufacturing Drugs 89

XTalks

MAY 10, 2024

Last year, the top healthcare companies not only showcased remarkable revenue figures but also demonstrated innovation, resilience and a commitment to improving healthcare delivery. This list highlights the top healthcare companies by 2023 revenue, providing a snapshot of their global influence, workforce and diverse services.

Pharmacy 52

Pharmacy Production 52

pharmaphorum

JULY 27, 2022

Pharma distributor AmerisourceBergen is working on a platform to make access to digital therapeutics (DTx) easier in the US by providing a unified system for ordering, dispensing and fulfilment. The post AmerisourceBergen aims to make digital therapeutics access easier appeared first on. billion in 2021.

Production 72

Production Pharma Companies Doctors Doctor 72

BioTech 365

SEPTEMBER 28, 2021

AmerisourceBergen Unveils New Global Headquarters in Conshohocken, PA & Announces Great Place to Work® Recognition AmerisourceBergen Unveils New Global Headquarters in Conshohocken, PA & Announces Great Place to Work® Recognition CONSHOHOCKEN, Pa.–(BUSINESS

40

40

Drug Channels

DECEMBER 14, 2023

These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. As I explain, AmerisourceBergen (Cencora) gains significant strategic advantage from this transaction, which echoes a historical McKesson deal.

Drugs 52

Drugs 52

BioTech 365

FEBRUARY 19, 2021

AmerisourceBergen Named Best Place to Work for LGBTQ Equality AmerisourceBergen Named Best Place to Work for LGBTQ Equality Company received 100 percent on Human Rights Campaign Foundation’s Annual Scorecard on LGBTQ Workplace Equality VALLEY FORGE, Pa.–(BUSINESS

52

52

World of DTC Marketing

MARCH 16, 2022

Besides the increased costs of prescription drugs above inflation levels, drug companies are playing a shell game with the opioid settlements. Analysts expect that “big biopharma” companies will collectively have more than $500 billion in cash to deploy by 2022.

Insulin 183

Insulin Packaging Packaging Production 183

World of DTC Marketing

JULY 6, 2022

million doses of oxycodone and hydrocodone to pharmacies in Cabell County and the city of Huntington over less than a decade, McKesson, AmerisourceBergen, and Cardinal Health didn’t cause an oversupply of opioids in the area, Judge David Faber ruled on Monday. Despite distributing more than 51.3 New York Times.

Pharmacy 238

Pharmacy Doctors Doctor Sales 238

Pharmaceutical Technology

DECEMBER 19, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Production 130

Production Marketing Manufacturing Research 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU.

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Drug Channels

OCTOBER 11, 2022

This 2022-23 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. Section 6.1.6. In some small way, I try to make the world a better and smarter place.

Licensing 57

Licensing Licensing Containment Drugs 57

pharmaphorum

NOVEMBER 2, 2022

The two companies have respectively agreed to pay $5 billion over 10 years and $5.7 The pharmacy chains are following in the footsteps of the big three US wholesaler distributors – McKesson, Cardinal Health and AmerisourceBergen – who agreed a $21 billion settlement earlier this year. billion for Teva Pharmaceutical , $2.4

Pharmacy 96

Pharmacy Manufacturing Medicine Sales 96

Pharmaceutical Technology

DECEMBER 22, 2022

The programme provides a platform to recognise the people and companies that are driving change. Our programme is designed to highlight excellence within the sector by looking at a range of corporate activities including deals, business projects and company initiatives, both internal and in the community. Business Expansion.

Insulin 130

Insulin Production Development Genetics 130

pharmaphorum

JULY 6, 2022

A court in West Virginia has ruled that US drug distributors McKesson, AmerisourceBergen and Cardinal Health are not responsible for fuelling the opioid crisis that has claimed thousands of lives in the state. District court judge David Faber rejected a call by prosecutors to force the distributors to pay $2.5

Doctors 59

Doctors Doctor Pharmacy Manufacturing 59

The Pharma Data

AUGUST 19, 2020

billion from opioid distributors including Cardinal Health, McKesson Corp and AmerisourceBergen. All the companies involved declined to comment. . The lawsuit accused the companies of insurance fraud and for downplaying the risks of their opioid painkillers to both doctors and patients. Both companies deny the charges. .

Manufacturing 52

Manufacturing Doctors Doctor Production 52

pharmaphorum

JANUARY 19, 2022

The announcement comes at the same time as the state has finalised its nearly $300 million (£220 million) settlement with Johnson & Johnson that was announced in July, part of a multi-state settlement deal that also included distributors AmerisourceBergen, Cardinal Health, and McKesson. Purdue Pharma, L.P.,

Marketing 52

Marketing Research 52

pharmaphorum

FEBRUARY 28, 2022

The settlement is the largest to date among thousands of opioid-related lawsuits brought against pharma companies and distributors. There are still some holdouts, as all four companies still face claims in Alabama, Oklahoma, Washington and West Virginia, and New Hampshire has so far refused to reach a settlement with J&J.

Sales 59

Sales Pharma Companies Marketing Production 59

BioSpace

DECEMBER 8, 2022

The two companies announced a collaboration to develop an intracellular Endosomal Escape Vehicle. Vertex Pharmaceuticals agreed to a collaboration deal with Entrada Therapeutics.

Development 40

Development Sales 40

pharmaphorum

DECEMBER 31, 2021

The complaint against Teva was brought in 2019, and accused the company of aggressively marketing opioid painkillers across New York and misleading the public about the harmful effects of the drugs. That decision swelled the settlements agreed with other companies targeted by the lawsuit to around $1.5 Letitia James.

Trials 52

Trials Packaging Packaging Marketing 52

pharmaphorum

NOVEMBER 16, 2022

The pharmacy chains are following in the footsteps of the big three US wholesaler distributors – McKesson, Cardinal Health, and AmerisourceBergen – who agreed a $21 billion settlement earlier this year. billion for Teva Pharmaceutical , $2.4 billion for AbbVie, $1.7 billion for Mallinckrodt , and $450 million for Endo Pharma.

Pharmacy 52

Pharmacy Regulation Manufacturing Drugs 52

Drug Channels

SEPTEMBER 12, 2023

The report also updates our annual analyses of the strategies, market positions, and executive compensation of the three largest companies: AmerisourceBergen (Cencora), Cardinal Health, and McKesson. As always, we have updated all market and industry data with the most current information available.

Pharmacy 52

Pharmacy Licensing Licensing Drugs 52

The Pharma Data

NOVEMBER 10, 2020

In October, the company announced that it had reached a $375 million deal to sell 300,000 doses of the treatment to the U.S. In early studies, researchers discovered those groups seemed to benefit the most from the treatment. government.

Antibody 52

Antibody Development Research 52

Pharmacy Checkers

JUNE 4, 2020

The main culprits in sowing this drug epidemic are usually identified as big pharmaceutical companies and distributors. Since the beginning of this century, billions of prescription opioid pills were wrongly, and in many cases unlawfully, pushed on and distributed to Americans. The result is about 500,000 deaths since 1999.

Pharmacy 56

Pharmacy Sales Drugs Medicine 56

Drug Channels

OCTOBER 5, 2021

This 2021-22 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. In some small way, I try to make the world a better and smarter place.

Licensing 63

Licensing Licensing Containment Pharmacy 63

pharmaphorum

JULY 21, 2021

Under the deal, J&J would be in line for a $5 billion payment over nine years, while wholesalers McKesson, Cardinal Health and AmerisourceBergen would share responsibility for the remaining $21 billion over an 18-year timeframe.

Sales 52

Sales Packaging Packaging Drugs 52

pharmaphorum

JUNE 28, 2021

While the company didn’t provide finished opioid drugs, J&J supplied raw materials used to make them, and has been accused by various US states of using deceptive marketing to say the drugs were effective for treating pain and were unlikely to cause addiction.

Marketing 52

Marketing Sales Manufacturing Production 52

Drug Channels

OCTOBER 10, 2023

No other report on the market today offers the depth, insight and analysis into these channels This 2023-24 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson.

Pharmacy 40

Pharmacy Licensing Licensing Containment 40

pharmaphorum

JANUARY 28, 2021

In fact, at AmerisourceBergen, we’re seeing health system customers actively engage us about biosimilars and how to integrate these products into their formularies and care plans. Sean McGowan is responsible for leading strategy and business development initiatives for the Biosimilar product category at AmeriSourceBergen.

Marketing 103

Marketing Insulin HR Production 103

Drug Channels

OCTOBER 13, 2020

This 2020-21 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. In some small way, I try to make the world a better and smarter place.

Licensing 52

Licensing Licensing Containment Pharmacy 52

The Pharma Data

MAY 4, 2021

RELATED: Companies collaborate on DSCSA guideline as deadlines approach , Regulatory Focus 26 November 2016). Brad Pine, the vice president of brand pharma and regulatory for Smith Drug Company, said that “our biggest challenge is getting manufacturers to send us EPCIS.” They said, ‘Oh, I have to send it to you?”

Manufacturing 52

Manufacturing Production Branding Drugs 52

pharmaphorum

APRIL 1, 2022

As a result, markets are expected to become more competitive, and it will show pharmaceutical companies that there’s ample opportunity to invest in the research and development of biosimilars. Elizabeth “Beth” McMahon is senior vice president of emerging therapies & channel strategy at AmerisourceBergen. About the author.

Marketing 59

Marketing Pharmacy FDA Approval Manufacturing 59

The Pharma Data

DECEMBER 17, 2020

Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Previously he was CFO of Voyager Therapeutics.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

JULY 27, 2022

The Israel-headquartered company – one of the largest suppliers of opioids in the US – said the tentative agreement is with states, Native American tribes and local plaintiffs and will involve payments over 13 years. billion, including already settled cases.

Sales 93

Sales Production Marketing 93

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Sites of care will then confirm their need and AmerisourceBergen will distribute bamlanivimab overnight. About Eli Lilly and Company?

Antibody 52

Antibody Medicine Manufacturing Trials 52

STAT News

AUGUST 2, 2022

… West Virginia cities and counties reached a $400 million settlement with McKesson, AmerisourceBergen and Cardinal Health to resolve the allegations that the three wholesalers fueled an opioid crisis in the state , Reuters notes. More Have a grand day, everyone, and do stay in touch.

96

96

pharmaphorum

JANUARY 4, 2023

Over the last two years, the company has doubled its cryogenic storage capacity across its global network of clinical and commercial depots. Andrea Zobel is the senior director of Personalized Supply Chain at World Courier, a global specialty logistics provider and a part of AmerisourceBergen. About the author.

Gene Therapy 97

Gene Therapy Manufacturing Gene Production 97

pharmaphorum

NOVEMBER 10, 2020

Lilly says it will ship supplies of the drug to AmerisourceBergen, which will handle distribution once a week in accordance with the US government’s allocation plans. The company says it hopes to be able to produce up to one million doses of bamlanivimab 700mg by the end of 2020, “for use around the world through early next year.”.

Drugs 103

Drugs Antibody Allergies FDA Approval 103